CorMedix Statistics
Total Valuation
CorMedix has a market cap or net worth of $847.81 million. The enterprise value is $770.78 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, before market open.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CorMedix has 67.82 million shares outstanding. The number of shares has increased by 13.79% in one year.
| Current Share Class | 74.43M |
| Shares Outstanding | 67.82M |
| Shares Change (YoY) | +13.79% |
| Shares Change (QoQ) | +12.14% |
| Owned by Insiders (%) | 1.08% |
| Owned by Institutions (%) | 35.81% |
| Float | 67.09M |
Valuation Ratios
The trailing PE ratio is 45.03 and the forward PE ratio is 12.28.
| PE Ratio | 45.03 |
| Forward PE | 12.28 |
| PS Ratio | 9.21 |
| Forward PS | 5.33 |
| PB Ratio | 7.37 |
| P/TBV Ratio | 7.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 44.87 |
| EV / Sales | 9.34 |
| EV / EBITDA | 51.65 |
| EV / EBIT | 53.26 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.21, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.21 |
| Quick Ratio | 3.84 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | n/a |
| Interest Coverage | 395.69 |
Financial Efficiency
Return on equity (ROE) is 19.87% and return on invested capital (ROIC) is 10.40%.
| Return on Equity (ROE) | 19.87% |
| Return on Assets (ROA) | 8.31% |
| Return on Invested Capital (ROIC) | 10.40% |
| Return on Capital Employed (ROCE) | 12.56% |
| Revenue Per Employee | $1.27M |
| Profits Per Employee | $264,308 |
| Employee Count | 65 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 0.81 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +201.21% in the last 52 weeks. The beta is 1.61, so CorMedix's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | +201.21% |
| 50-Day Moving Average | 11.99 |
| 200-Day Moving Average | 10.21 |
| Relative Strength Index (RSI) | 43.85 |
| Average Volume (20 Days) | 2,302,121 |
Short Selling Information
The latest short interest is 8.59 million, so 12.66% of the outstanding shares have been sold short.
| Short Interest | 8.59M |
| Short Previous Month | 8.53M |
| Short % of Shares Out | 12.66% |
| Short % of Float | 12.80% |
| Short Ratio (days to cover) | 6.18 |
Income Statement
In the last 12 months, CorMedix had revenue of $82.55 million and earned $17.18 million in profits. Earnings per share was $0.28.
| Revenue | 82.55M |
| Gross Profit | 78.59M |
| Operating Income | 14.47M |
| Pretax Income | n/a |
| Net Income | 17.18M |
| EBITDA | 14.92M |
| EBIT | 14.47M |
| Earnings Per Share (EPS) | $0.28 |
Full Income StatementBalance Sheet
The company has $77.50 million in cash and $476,587 in debt, giving a net cash position of $77.03 million or $1.14 per share.
| Cash & Cash Equivalents | 77.50M |
| Total Debt | 476,587 |
| Net Cash | 77.03M |
| Net Cash Per Share | $1.14 |
| Equity (Book Value) | 114.89M |
| Book Value Per Share | 1.70 |
| Working Capital | 110.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.57 million and capital expenditures -$64,601, giving a free cash flow of -$13.63 million.
| Operating Cash Flow | -13.57M |
| Capital Expenditures | -64,601 |
| Free Cash Flow | -13.63M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
Gross margin is 95.19%, with operating and profit margins of 17.53% and 20.81%.
| Gross Margin | 95.19% |
| Operating Margin | 17.53% |
| Pretax Margin | 20.81% |
| Profit Margin | 20.81% |
| EBITDA Margin | 18.08% |
| EBIT Margin | 17.53% |
| FCF Margin | n/a |
Dividends & Yields
CorMedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.79% |
| Shareholder Yield | -13.79% |
| Earnings Yield | 2.03% |
| FCF Yield | -1.61% |
Analyst Forecast
The average price target for CorMedix is $16.00, which is 28.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.00 |
| Price Target Difference | 28.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 49.05% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on March 26, 2019. It was a reverse split with a ratio of 0.2:1.
| Last Split Date | Mar 26, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.2:1 |
Scores
CorMedix has an Altman Z-Score of 6.54 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.54 |
| Piotroski F-Score | 2 |
